Sartorius receives award for outstanding performance in its production chain

8 Nov 2018

Company's manufacturing building for laboratory instruments in Göttingen wins the Global Excellence in Operations Award.

Manufacturing operations at Sartorius has received a prize for outstanding performance in its value creation chain. At the competition for the Factory of the Year 2018 Award hosted annually by the German production trade journal Produktion and the global management consulting firm A.T. Kearney, the Sartorius manufacturing building for laboratory instruments in Göttingen won the GEO Award – Global Excellence in Operations. This prize will be conferred to Sartorius in March 2019 at the GEO Conference in Ludwigsburg, Germany.

Sartorius receives award for outstanding performance in its production chain

Each of the competing production chains was assessed by performance indicators that were benchmarked, such as customer satisfaction, quality or innovation. These, in turn, involved several assessment criteria, including cost management, resource efficiency and customer focus.

“Our thanks go out to the entire team that faced up to the challenges posed by the competition and to all staff members who have shaped the transformative activities over the past years and helped to implement the changes and improvements. With our drive to provide customers with the best possible service, I see the Global Excellence in Operation Award as confirmation that we are on the right track, and as an incentive to go forward,” said Matthias Wessel, Head of Operations of the Sartorius Lab Products & Services Division.

Around 450 employees manufacture laboratory instruments, such as balances, ultrapure water systems and moisture analysers in the building covering some 25,000 m2. As high-precision weighing instruments are also calibrated inside, the building is protected from temperature fluctuations and by a vibration-decoupled foundation.

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more